University of Chicago Bacteriophage Patent for Bacterial Infections
Summary
The University of Chicago has received a published patent application (US20260108570A1) for bacteriophage compositions and methods targeting Enterobacteriaceae infections, including Klebsiella. The application, filed August 1, 2023, covers isolated bacteriophage sequences with at least 99% identity to SEQ ID NO:1-74, along with associated devices, kits, and treatment methods. Inventors include Mark MIMEE and Ella ROTMAN.
“Disclosed are compositions, devices, kits, and methods for treatment of Enterobacteriaceae infection.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
The USPTO has published patent application US20260108570A1, assigned to the University of Chicago, covering bacteriophage compositions for treating bacterial infections. The application discloses isolated bacteriophage with sequences at least 99% identical to SEQ ID NO:1-74, along with devices, kits, and methods for treatment and prevention of pathogenic Klebsiella infections.
Entities in the pharmaceutical and biotechnology sectors should review this publication to assess potential licensing opportunities or freedom-to-operate considerations, particularly for firms developing phage-based antimicrobial therapies targeting drug-resistant Enterobacteriaceae.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
BACTERIOPHAGE COMPOSITIONS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS
Application US20260108570A1 Kind: A1 Apr 23, 2026
Assignee
THE UNIVERSITY OF CHICAGO
Inventors
Mark MIMEE, Ella ROTMAN
Abstract
Disclosed are compositions, devices, kits, and methods for treatment of Enterobacteriaceae infection. Aspects of the present disclosure are directed to bacteriophage compositions comprising one or more isolated bacteriophage comprising a bacterio-phage sequence that is at least 99% identical to any one of SEQ ID NO:1-74. Further disclosed are devices and kits comprising such compositions and methods for use of such compositions in treatment and prevention of pathogenic Klebsiella infection.
CPC Classifications
A61K 35/76 A61P 43/00 C12N 7/02
Filing Date
2023-08-01
Application No.
19100379
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.